Long-term androgen deprivation increases Grade 2 and higher late morbidity in prostate cancer patients treated with three-dimensional conformal radiation therapy

International Journal of Radiation Oncology Biology Physics

Volumn 62, Issue 2, 2005, Pages 397-405

  Feigenberg, Steven J ^a   Hanlon, Alexandra L ^a   Horwitz, Eric M ^a   Uzzo, Robert G ^a   Eisenberg, Debra ^a   Pollack, Alan ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

3D CRT; Gastrointestinal genitourinary morbidity; Hormones; Prostate cancer

Indexed keywords

ANTIGENS; GASTROENTEROLOGY; PATIENT TREATMENT; RADIATION EFFECTS; TUMORS;

ANDROGEN DEPRIVATION; CONFORMAL RADIATION THERAPY (CRT); INDEPENDENT PREDICTORS; PROSTATE CANCER;

RADIOLOGY;

ANDROGEN; ANTIANDROGEN; GONADORELIN DERIVATIVE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RADIOTHERAPY; CONTROLLED STUDY; DIABETES MELLITUS; GASTROINTESTINAL TOXICITY; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTIVARIATE ANALYSIS OF COVARIANCE; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RADIATION FIELD; RADIATION INJURY; RISK ASSESSMENT; UROGENITAL TRACT DISEASE;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; COMBINED MODALITY THERAPY; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TRACT; HUMANS; MALE; MIDDLE AGED; MORBIDITY; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL; RECTUM; REGRESSION ANALYSIS; TIME FACTORS; UROGENITAL SYSTEM;

EID: 18944394695     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2004.10.021     Document Type: Article

References (38)

1. C.A. Lawton Hormones and radiation therapy in locally advanced adenocarcinoma of the prostate Semin Radiat Oncol 13 2003 141 151
2. M. Bolla, D. Gonzalez, P. Warde Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin N Engl J Med 337 1997 295 300
3. M. Bolla, L. Collette, L. Blank Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study) A phase III randomised trial Lancet 360 2002 103 106
4. M. Roach 3rd, M. DeSilvio, C. Lawton Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression Radiation Therapy Oncology Group 9413 J Clin Oncol 21 2003 1904 1911
5. M.V. Pilepich, R. Caplan, R.W. Byhardt Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy Report of Radiation Therapy Oncology Group Protocol 85-31 J Clin Oncol 15 1997 1013 1021
6. M.V. Pilepich, K. Winter, M.J. John Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate Int J Radiat Oncol Biol Phys 50 2001 1243 1252
7. M. Pilepich Androgen suppression adjuvant to radiotherapy in carcinoma of the prostate. Long-term results of Phase III RTOG study 85-31 Int J Radiat Oncol Biol Phys 57 2003 S172 S173
8. M.J. Zelefsky, S.A. Leibel, P.B. Gaudin Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer Int J Radiat Oncol Biol Phys 41 1998 491 500
9. M.J. Zelefsky, Z. Fuks, L. Happersett Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer Radiother Oncol 55 2000 241 249
10. A. Pollack, L.G. Smith, A.C. von Eschenbach External beam radiotherapy dose response characteristics of 1,127 men with prostate cancer treated in the PSA era Int J Radiat Oncol Biol Phys 48 2000 507 512
11. J.A. Lyons, P.A. Kupelian, D.S. Mohan Importance of high radiation doses (72 Gy or greater) in the treatment of stage T1-T3 adenocarcinoma of the prostate Urology 55 2000 85 90
12. A. Martinez, J. Gonzalez, W. Spencer Conformal high dose rate brachytherapy improves biochemical control and cause specific survival in patients with prostate cancer and poor prognostic factors J Urol 169 2003 974 979 discussion 979-980
13. G.E. Hanks, A.L. Hanlon, B. Epstein Dose response in prostate cancer with 8-12 years' follow-up Int J Radiat Oncol Biol Phys 54 2002 427 435
14. A. Pollack, G.K. Zagars, G. Starkschall Prostate cancer radiation dose response Results of the M. D. Anderson Phase III randomized trial Int J Radiat Oncol Biol Phys 53 2002 1097 1105
15. A. Pollack, G.K. Zagars, L.G. Smith Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer J Clin Oncol 18 2000 3904 3911
16. W.J. Curran Jr, H. Choy Optimizing chemoradiation in locally advanced non-small-cell lung cancer Oncology (Huntingt) 15 2001 43 45
17. A. Herskovic, K. Martz, M. al-Sarraf Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus N Engl J Med 326 1992 1593 1598
18. G.E. Hanks, T.F. Pajak, A. Porter Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate the Radiation Therapy Oncology Group Protocol 92-02 J Clin Oncol 21 2003 3972 3978
19. G. Sanguineti, S. Agostinelli, F. Foppiano Adjuvant androgen deprivation impacts late rectal toxicity after conformal radiotherapy of prostate carcinoma Br J Cancer 86 2002 1843 1847
20. E.M. Horwitz, A.L. Hanlon, W.H. Pinover Defining the optimal radiation dose with three-dimensional conformal radiation therapy for patients with nonmetastatic prostate carcinoma by using recursive partitioning techniques Cancer 92 2001 1281 1287
21. G.E. Hanks, T.E. Schultheiss, A.L. Hanlon Optimization of conformal radiation treatment of prostate cancer Report of a dose escalation study Int J Radiat Oncol Biol Phys 37 1997 543 550
22. A.F. Monti, A. Ostinelli, M. Frigerio An ICRU 50 radiotherapy treatment chart Radiother Oncol 35 1995 145 150
23. A.L. Hanlon, T.E. Schultheiss, M.A. Hunt Chronic rectal bleeding after high-dose conformal treatment of prostate cancer warrants modification of existing morbidity scales Int J Radiat Oncol Biol Phys 38 1997 59 63
24. E.L. Kaplan, P. Meier Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 447 457
25. F. Wilcoxon Individual comparison by ranking methods Biometrics 1 1945 80 83
26. D.R. Cox Regression models and life tables J R Stat Soc 34 1972 187 220
27. M. Bolla, D. Gonzalez, P. Warde Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin N Engl J Med 337 1997 295 300
28. M.V. Pilepich, R. Caplan, R.W. Byhardt Phase III trial of androgen suppression using Goserelin in unfavorable prognosis carcinoma of the prostate treated with definitive radiotherapy--report of RTOG 85-31 J Clin Oncol 15 1997 1013 1021
29. T. Granfors, H. Modig, J. Damber Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement A prospective randomized study J Urol 159 1998 2030 2034
30. C. Fiorino, C. Cozzarini, V. Vavassori Relationships between DVHs and late rectal bleeding after radiotherapy for prostate cancer Analysis of a large group of patients pooled from three institutions Radiother Oncol 64 2002 1 12
31. E.H. Huang, A. Pollack, L. Levy Late rectal toxicity Dose-volume effects of conformal radiotherapy for prostate cancer Int J Radiat Oncol Biol Phys 54 2002 1314 1321
32. M.W. Skwarchuk, A. Jackson, M.J. Zelefsky Late rectal toxicity after conformal radiotherapy of prostate cancer (I) Multivariate analysis and dose-response Int J Radiat Oncol Biol Phys 47 2000 103 113
33. T.E. Schultheiss, W.R. Lee, M.A. Hunt Late GI and GU complications in the treatment of prostate cancer Int J Radiat Oncol Biol Phys 37 1997 3 11
34. R.K. Valicenti, K. Winter, J.D. Cox RTOG 94-06 Is the addition of neoadjuvant hormonal therapy to dose-escalated 3D conformal radiation therapy for prostate cancer associated with treatment toxicity? Int J Radiat Oncol Biol Phys 57 2003 614 620
35. M.J. Zelefsky, A. Harrison Neoadjuvant androgen ablation prior to radiotherapy for prostate cancer Reducing the potential morbidity of therapy Urology 49 1997 38 45
36. J.D. Forman, R. Kumar, G. Haas Neoadjuvant hormonal downsizing of localized carcinoma of the prostate Effects on the volume of normal tissue irradiation Cancer Invest 13 1995 8 15
37. M.E. Gleave, S.L. Goldenberg, J.L. Chin Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy Biochemical and pathological effects J Urol 166 2001 500 506 discussion 506-507
38. L.R. Coia, R.J. Myerson, J.E. Tepper Late effects of radiation therapy on the gastrointestinal tract Int J Radiat Oncol Biol Phys 31 1995 1213 1236